Retraction notice to “Thymoquinone poly(lactide-co-glycolide) nanoparticles exhibit enhanced anti-proliferative, anti-inflammatory, and chemosensitization potential” [Biochem. Pharmacol. 79 (2010) 1640–1647]
Jayaraj Ravindrana, Hareesh B. Nairb, Bokyung Sunga, Sahdeo Prasada, Rajeshwar R. Tekmalb, Bharat B. Aggarwala,*
a Cytokine Research Laboratory, Department of Experimental Therapeutics, The University of Texas M.D. Anderson Cancer Center, Houston, TX, United States
b Department of Obstetrics and Gynecology, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, United States
This article has been retracted: please see Elsevier Policy on Article Withdrawal (http://www.elsevier.com/locate/withdrawalpolicy).
This article has been retracted at the request of the Editor.
An image in Fig. 6 was reused to represent two different experimental conditions: images of paclitaxel alone (“Paclitaxel”) and of thymoquinone plus paclitaxel (“TQ + Paclitaxel”) are manipulations of the same image.
The article has been retracted because the data integrity has become questionable.
* Corresponding author at: Cytokine Research Laboratory, Department of Experimental Therapeutics, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Box 143, Houston, TX 77030, United States. Tel.: +1 713 794 1817; fax: +1 713 794 1613. aggarwal@mdanderson.org (B.B. Aggarwal).